Lamivudine for hepatitis B in clinical practice

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Lamivudine is a potent, once-daily, oral antiviral therapy that is effective and well tolerated in most patient groups with chronic hepatitis B virus infection, including those with pre-core mutant infection. Studies to date show that lamivudine suppresses serum viral replication, causing reductions in serum hepatitis B virus (HBV) DNA and enhancing hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg plus presence of antibodies to HBeAg [anti-HBe]). Lamivudine also improves liver disease, as shown by normalisation of alanine transaminase (ALT) levels and reduced progression to cirrhosis. Lamivudine is effective in patients who are interferon (IFN) alpha naive and in those who have failed to respond to IFN alpha, and it suppresses HBV in decompensated liver disease and in liver transplantation. Variants with mutations in the YMDD (tyrosine-methionine-aspartate-aspartate) motif may emerge with prolonged lamivudine therapy, but most patients maintain clinical control. Lamivudine has a safety profile similar to that of placebo and it is better tolerated than IFN alpha. In conclusion, lamivudine represents a major advance in the therapeutic options available for the management of patients with chronic hepatitis B and should now be considered the drug of choice for most patients who require treatment. (C) 2000 Wiley- Liss, Inc.

Original languageEnglish
Pages (from-to)386-391
Number of pages6
JournalJournal of Medical Virology
Volume61
Issue number3
DOIs
StatePublished - Jun 27 2000

Fingerprint

Lamivudine
Hepatitis B
Hepatitis B e Antigens
Hepatitis B virus
Interferon-alpha
Chronic Hepatitis B
Aspartic Acid
Liver Diseases
Virus Diseases
Therapeutics
Serum
Alanine Transaminase
Methionine
Liver Transplantation
Antiviral Agents
Tyrosine
Fibrosis
Placebos
Safety
Mutation

Keywords

  • Chronic hepatitis B
  • Nucleoside analogue
  • Safety
  • Treatment
  • YMDD variant

ASJC Scopus subject areas

  • Virology

Cite this

Lamivudine for hepatitis B in clinical practice. / Schiff, Eugene R.

In: Journal of Medical Virology, Vol. 61, No. 3, 27.06.2000, p. 386-391.

Research output: Contribution to journalArticle

@article{fba3984115d045d28cf2cc01e63994c6,
title = "Lamivudine for hepatitis B in clinical practice",
abstract = "Lamivudine is a potent, once-daily, oral antiviral therapy that is effective and well tolerated in most patient groups with chronic hepatitis B virus infection, including those with pre-core mutant infection. Studies to date show that lamivudine suppresses serum viral replication, causing reductions in serum hepatitis B virus (HBV) DNA and enhancing hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg plus presence of antibodies to HBeAg [anti-HBe]). Lamivudine also improves liver disease, as shown by normalisation of alanine transaminase (ALT) levels and reduced progression to cirrhosis. Lamivudine is effective in patients who are interferon (IFN) alpha naive and in those who have failed to respond to IFN alpha, and it suppresses HBV in decompensated liver disease and in liver transplantation. Variants with mutations in the YMDD (tyrosine-methionine-aspartate-aspartate) motif may emerge with prolonged lamivudine therapy, but most patients maintain clinical control. Lamivudine has a safety profile similar to that of placebo and it is better tolerated than IFN alpha. In conclusion, lamivudine represents a major advance in the therapeutic options available for the management of patients with chronic hepatitis B and should now be considered the drug of choice for most patients who require treatment. (C) 2000 Wiley- Liss, Inc.",
keywords = "Chronic hepatitis B, Nucleoside analogue, Safety, Treatment, YMDD variant",
author = "Schiff, {Eugene R}",
year = "2000",
month = "6",
day = "27",
doi = "10.1002/1096-9071(200007)61:3<386::AID-JMV18>3.0.CO;2-X",
language = "English",
volume = "61",
pages = "386--391",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Lamivudine for hepatitis B in clinical practice

AU - Schiff, Eugene R

PY - 2000/6/27

Y1 - 2000/6/27

N2 - Lamivudine is a potent, once-daily, oral antiviral therapy that is effective and well tolerated in most patient groups with chronic hepatitis B virus infection, including those with pre-core mutant infection. Studies to date show that lamivudine suppresses serum viral replication, causing reductions in serum hepatitis B virus (HBV) DNA and enhancing hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg plus presence of antibodies to HBeAg [anti-HBe]). Lamivudine also improves liver disease, as shown by normalisation of alanine transaminase (ALT) levels and reduced progression to cirrhosis. Lamivudine is effective in patients who are interferon (IFN) alpha naive and in those who have failed to respond to IFN alpha, and it suppresses HBV in decompensated liver disease and in liver transplantation. Variants with mutations in the YMDD (tyrosine-methionine-aspartate-aspartate) motif may emerge with prolonged lamivudine therapy, but most patients maintain clinical control. Lamivudine has a safety profile similar to that of placebo and it is better tolerated than IFN alpha. In conclusion, lamivudine represents a major advance in the therapeutic options available for the management of patients with chronic hepatitis B and should now be considered the drug of choice for most patients who require treatment. (C) 2000 Wiley- Liss, Inc.

AB - Lamivudine is a potent, once-daily, oral antiviral therapy that is effective and well tolerated in most patient groups with chronic hepatitis B virus infection, including those with pre-core mutant infection. Studies to date show that lamivudine suppresses serum viral replication, causing reductions in serum hepatitis B virus (HBV) DNA and enhancing hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg plus presence of antibodies to HBeAg [anti-HBe]). Lamivudine also improves liver disease, as shown by normalisation of alanine transaminase (ALT) levels and reduced progression to cirrhosis. Lamivudine is effective in patients who are interferon (IFN) alpha naive and in those who have failed to respond to IFN alpha, and it suppresses HBV in decompensated liver disease and in liver transplantation. Variants with mutations in the YMDD (tyrosine-methionine-aspartate-aspartate) motif may emerge with prolonged lamivudine therapy, but most patients maintain clinical control. Lamivudine has a safety profile similar to that of placebo and it is better tolerated than IFN alpha. In conclusion, lamivudine represents a major advance in the therapeutic options available for the management of patients with chronic hepatitis B and should now be considered the drug of choice for most patients who require treatment. (C) 2000 Wiley- Liss, Inc.

KW - Chronic hepatitis B

KW - Nucleoside analogue

KW - Safety

KW - Treatment

KW - YMDD variant

UR - http://www.scopus.com/inward/record.url?scp=0034040935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034040935&partnerID=8YFLogxK

U2 - 10.1002/1096-9071(200007)61:3<386::AID-JMV18>3.0.CO;2-X

DO - 10.1002/1096-9071(200007)61:3<386::AID-JMV18>3.0.CO;2-X

M3 - Article

C2 - 10861651

AN - SCOPUS:0034040935

VL - 61

SP - 386

EP - 391

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 3

ER -